InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime 80 cm stent implant in the second half of this year.

Key 30-day outcomes observed in the CGUARDIANS II trial include:

• Acute device success was achieved in 100% (50/50) of patients;
• No deaths, strokes, or myocardial infarctions were reported within 30 days;
• No stent thrombosis was observed within 30 days;
• Complete stent patency observed at 30 days in evaluable subjects.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.